- Home
- NVO vs AZN Comparison
NVO vs AZN Comparison
Compare NVO & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVO
- AZN
- Stock Information
- Founded
- NVO 1923
- AZN 1992
- Country
- NVO Denmark
- AZN United Kingdom
- Employees
- NVO N/A
- AZN N/A
- Industry
- NVO Biotechnology: Biological Products (No Diagnostic Substances)
- AZN Biotechnology: Pharmaceutical Preparations
- Sector
- NVO Health Care
- AZN Health Care
- Exchange
- NVO Nasdaq
- AZN Nasdaq
- Market Cap
- NVO 278.0B
- AZN 252.9B
- IPO Year
- NVO N/A
- AZN 1993
- Fundamental
- Price
- NVO $54.92
- AZN $79.56
- Analyst Decision
- NVO Buy
- AZN Strong Buy
- Analyst Count
- NVO 7
- AZN 1
- Target Price
- NVO $98.00
- AZN N/A
- AVG Volume (30 Days)
- NVO 14.9M
- AZN 3.4M
- Earning Date
- NVO 11-05-2025
- AZN 11-11-2025
- Dividend Yield
- NVO 2.24%
- AZN 1.93%
- EPS Growth
- NVO 24.25
- AZN 28.86
- EPS
- NVO 3.93
- AZN 5.31
- Revenue
- NVO $49,108,936,497.00
- AZN $56,501,000,000.00
- Revenue This Year
- NVO $10.01
- AZN $10.57
- Revenue Next Year
- NVO $9.93
- AZN $6.25
- P/E Ratio
- NVO $13.90
- AZN $29.88
- Revenue Growth
- NVO 20.91
- AZN 15.00
- 52 Week Low
- NVO $45.05
- AZN $61.24
- 52 Week High
- NVO $138.22
- AZN $82.41
- Technical
- Relative Strength Index (RSI)
- NVO 46.80
- AZN 52.96
- Support Level
- NVO $53.55
- AZN $80.58
- Resistance Level
- NVO $55.24
- AZN $81.31
- Average True Range (ATR)
- NVO 1.17
- AZN 1.07
- MACD
- NVO 0.19
- AZN -0.34
- Stochastic Oscillator
- NVO 39.06
- AZN 14.29
About NVO Novo Nordisk A/S
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.